TransMedics Group Inc (HAM:8T8)

Q2 2026 Transmedics Group Inc Earnings Call Transcript

Aug 4, 2026 / 08:30 PM GMT

Release Date Price: €69.56 (+6.98%)

Transcript 10-Q8-K

Key Points

Positve

Record Q2 2026 revenue of ~$190 million, up 21% year-over-year and 9% sequentially, with strong growth across all organ segments.
Service revenue surged 29% year-over-year and 19% sequentially, driven by logistics market share gains and improved service margins (35% in Q2 vs. 27% in Q1).
TransMedics Logistics delivered ~$41 million in revenue, up 39% year-over-year, with 86% of NOP air missions covered internally, enhancing operational efficiency.
Raised the low end of full-year 2026 revenue guidance to $737-$757 million (22%-25% growth), excluding PAD Aviation contribution, reflecting confidence in continued momentum.
Strong cash position of ~$473 million, enabling self-funding of strategic growth initiatives, including OCS Kidney, NextGen platform, and European expansion.
Strategic investment in PAD Aviation (Germany) establishes a European logistics hub, enabling participation in regional transplant tenders and expanding international TAM.
OCS Kidney program progressing with pre-IDE discussions with FDA, targeting first clinical experience in 2027, addressing a massive US kidney transplant market (21,000+ annual transplants).
Enhanced Part B and De Novo clinical programs advancing, with IDE supplement for CHOPS submitted and expected approval by late Q3/early Q4, unlocking incremental heart and lung cases.
New donor and recipient screening coordination service launched July 1, 2026, with a major Boston healthcare system, expanding platform value and workflow integration.
Management reiterated long-term growth target of ~30,000 transplants and >$2 billion annual revenue by 2032, with a clear roadmap of four key initiatives.

Negative

Adjusted operating margin declined to 13.6% in Q2 2026, down from 18.5% in 2025, due to increased strategic investments, and full-year 2026 margin guidance was lowered to 12.5%-14%.
Adjusted operating expenses rose 46% year-over-year, driven by heavy R&D spending (up 99%) on OCS Kidney, NextGen, and clinical programs, with no near-term operating leverage.
Gross margin declined 180 basis points year-over-year to 59.6%, impacted by higher service mix and temporary product cost pressures, with service margins expected to normalize in H2.
PAD Aviation acquisition will be dilutive to gross and operating margins in the near term, with no revenue contribution assumed in 2026 guidance and limited financial visibility.
Enhanced Part B and De Novo clinical programs have been delayed, with minimal contribution in Q2 and no meaningful revenue expected until late Q4 2026 or 2027, creating uncertainty.
Q3 2026 is expected to be seasonally soft, with management cautioning that July's strong performance may not sustain through August and September.
International expansion remains early-stage, with only ~$5 million in Q2 international revenue (up 26% year-over-year), and European reimbursement and logistics tenders are still in progress.
The OCS Kidney program is in early development, with first clinical experience not expected until 2027, and regulatory approval and commercialization are years away.
The company's growth strategy relies heavily on regulatory approvals (e.g., FDA IDE for CHOPS, CMS OPO decision), which are subject to delays and external factors beyond management's control.
Management declined to provide 2027 operating margin or earnings guidance, citing uncertainty in clinical program timelines and investment pace, leaving investors without clear near-term profitability expectations.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TMDX.OQ - TransMedics Group, Inc.
Q2 2026 Transmedics Group Inc Earnings Call
Aug 04, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to TransMedic's Second Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Hannah Jeffrey from the Gilmartin Group for a few introductory comments.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Earlier today, TransMedix released financial results for the quarter ended June 30th, 2026. A copy of the press

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.